Authors
Dongjun Li, Oluwabukola Bamishaye, Sandi Li, Jingjuan Qiao, Francis Akinlotan, Farzaneh Dorabadizare, Xuxin Chen, Yijan Fan, Yi Yuan, Zongxiang Gui, Khan Hekmatyar, Éva Tóth, Agnès Pallier, Yiting Xu, Yusheng Zhang, Xiaofeng Ke, Alton B Farris, Hua Yang, Jian-Xiong Wang, Jennifer Carlisle, Suresh S Ramalingam, Michael Kirberger, Hans Grossniklaus, Xiaofeng Yang, Zhiren Liu, Wei Zhou, Jenny J Yang
Published in
Science advances. Volume 12. Issue 37. Pages eadz6815. Sep 11, 2026. Epub Sep 09, 2026.
Abstract
Lung cancer with multiorgan metastasis remains the leading cause of cancer death. Current CT imaging and biopsy are suboptimal for detecting early tumors or subclinical metastases. We address this gap using LUAD with LKB1/STK11 inactivation, which alters collagen via focal adhesion kinase activation. Collagen I overexpression in the tumor microenvironment and invasive edge was identified as a biomarker. We developed hProCA32.Collagen, a protein MRI contrast agent targeting collagen I, which exhibits 10-fold higher relaxivity than clinical GBCAs, with strong Gd3+ binding, high stability, and low toxicity risk. Precision MRI with hProCA32.Collagen enables early, noninvasive detection and quantification of lung tumors and metastases with improved contrast, outperforming CT and standard MRI. This is a demonstration of simultaneous MRI detection of primary tumors and metastases in the lung and adrenal glands, with collagen mapping. This approach offers a radiation-free tool for early diagnosis, staging, and monitoring in LUAD.
PMID:
42715331
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 26
- Comments 0